NGM Biopharmaceuticals IncNGM Biopharmaceuticals Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

This ESG rating covers 17 United Nations SDGs including: 'Clean Water & Sanitation', 'Climate Action' and 'Peace, Justice & Strong Institutions'. Full ESG assessment of NGM Biopharmaceuticals Inc are accessed by logging in. The report of NGM Biopharmaceuticals Inc incorporates information from across the web and also from available documents by NGM Biopharmaceuticals Inc.

NGM Biopharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.4; made up of an environmental score of 3.2, social score of 4.8 and governance score of 5.3.

SDG Transparency Score for NGM Biopharmaceuticals Inc 
Low
0 - 3

4.4

Medium Impact
4 - 6
High
7 - 10
Last Score Update: 2023-07-01
What drives the score for NGM Biopharmaceuticals Inc 
3.2

Environmental

4.8

Social

5.3

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
1252Wntresearch AB
4.5
High
1252Verano Holdings Corp
4.5
High
1284NGM Biopharmaceuticals Inc
4.4
High
1284Adinath Biolabs Ltd
4.4
High
1284Aligos Therapeutics Inc
4.4
High
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does NGM Biopharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc report the average age of the workforce?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc offer flexible work?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc conduct supply chain audits?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc disclose water use targets?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did NGM Biopharmaceuticals Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has NGM Biopharmaceuticals Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is NGM Biopharmaceuticals Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc disclose its waste policy?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc disclose energy use targets?

LockedSign up for free to unlock

Does NGM Biopharmaceuticals Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does NGM Biopharmaceuticals Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for NGM Biopharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

Sorry!

Failed to process!